HypoSkin®
The first skin model to inject in human outside of an actual patient
Immunocompetent
HypoSkin® models hold the features and functionalities of in vivo human skin, with all cells and appendages, to generate predictive human data.
Standardized
The models are standardized for reproducible research and testing on real, live human epidermis, dermis and adipose tissue.
Injection
The HypoSkin® model is the only human skin model on the market to study live response to subcutaneous and intradermal injection.
Platform
HypoSkin® is suitable for a broad range of drug and vaccine development studies, from PK/PD to immunotoxicity and cytotoxicity.
HypoSkin®
The only human skin model to study subcutaneous injections
Genoskin has developed an ex vivo human skin model including fat tissue. Hyposkin® is a full thickness living skin model and contains the three skin layers: epidermis, dermis and hypodermis.
More and more drugs are administered subcutaneously like cancer treatments, anti-inflammatory agents, vaccins, dermal fillers, etc. Biologics represent a significant portion of those. The ex vivo human Hyposkin® platform allows efficacy and toxicity testing as well as compounds absorption and metabolism studies.
The HypoSkin® project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 816289 (SME Instrument).
HypoSkin: The answer to the challenge of subcutaneously administered therapeutics development
The current lack of research tools to study injections in humans makes development of such therapeutic molecules very challenging, especially when animal testing is the only option for companies as they are not providing enough reliable and translationable data.
Hyposkin®, and all of Genoskin’s platforms using its technology, will support your drug development by delivering relevant and accurate data in immuno-toxicity, efficacy or metabolism field.
HypoSkin®
A fully immunocompetent living skin model
Therefore it can be used to assess immunotoxicity such as injection site reaction and efficacy such as T-cell mediated inflammation or vaccines immunogenicity.
Hypo-InflammaSkin: a psoriasis model to study subcutaneous injections of anti-inflammatory biologics
a proof-of-concept case study
The HypoSkin technology was combined with the InflammaSkin model to evaluate the efficacy of subcutaneous psoriasis biologics adalimumab.
HypoSkin® comes in different sizes to meet any subcutaneous injections need
HypoSkin® comes in a standardized 10 mm thickness to assess skin response to subcutaneous injections and topical or systemic administration.
